Tag:
personalized medicine
Latest Headlines
Latest Headlines
Roche invests $258M-plus into Germany Dx plant expansion
Roche Diagnostics plans to pour more than $258 million into building a new diagnostics production complex in Germany, thanks to rising demand for immunoassays of all kinds.
Biomarkers making a difference in clinical trials
Biomarkers play a major role in personalized medicine, supporting diagnosis and identifying those patients who are (or aren't) likely to respond, and supporting drugs through clinical trials.
GNS turns to Big Data to crack multiple myeloma
GNS Healthcare has teamed up with Dana-Farber and Mount Sinai to build a Big Data-driven computer model of multiple myeloma. The project will combine GNS' computing power with data from next-generation sequencing to support the development of personalized medicines.
Advanced Cell Diagnostics to fuel expansion with $12M Series B
Advanced Cell Diagnostics is kicking up a major expansion now that it has reeled in a $12 million Series B round of financing.
Deloitte scoops up Recombinant for data warehousing and analytics
The move gives the consulting giant the keys to Newton, MA-based Recombinant Data's growing business that serves the data needs of hospitals, research institutions and healthcare companies.
Five3, maker of cancer genomics software, takes off from UCSC labs
A group from the University of California, Santa Cruz, has embarked on a new project to commercialize cancer genomics software through a new startup company called Five3 Genomics. The company has attracted a few of the biggest names in genomics and biotech to serve as advisers.
Oracle, IBM support $100M personalized medicine effort at UPMC
The Pittsburgh-based health group has tapped Oracle, IBM, Informatica and dbMotion for technology in the $100 million project, which will give clinicians, researchers, administrators and others real-time access to data and analytics, UPMC announced Oct. 1.
Life Technologies, CollabRx forge molecular Dx data deal
Life Technologies ($LIFE) just sealed a multi-year deal with CollabRx ($CLRX) intended to supercharge the value of its molecular diagnostics tests with lots of data.
Avatar mice up ante for personalized drug treatment research
There's a new trend in research: using mice as avatars, or stand-ins, of sorts--personal guinea pigs for patients seeking the best possible cancer treatment.
Breast cancer gene finding upends Dx methodology
A finding that there are four main genetic subtypes of breast cancer creates enormous new opportunities for diagnostics companies. And the research, conducted by the Cancer Genome Atlas project and published in the journal Nature, could further upend the diagnostics industry as the science behind personalized medicine continues to advance, Bloomberg reports.
